06:47:29 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2026-02-20 Year-end Report 2025
2025-11-21 Quarterly Report 2025-Q3
2025-08-22 Quarterly Report 2025-Q2
2025-05-22 Quarterly Report 2025-Q1
2025-02-21 Year-end Report 2024
2024-11-21 Quarterly Report 2024-Q3
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend ABLI 0.00 SEK
2024-05-23 Quarterly Report 2024-Q1
2024-05-23 Annual General meeting
2024-03-26 Extra General Meeting 2024
2024-02-23 Year-end Report 2023
2023-11-17 Quarterly Report 2023-Q3
2023-08-18 Quarterly Report 2023-Q2
2023-05-23 Quarterly Report 2023-Q1
2023-05-08 Ex-date Ordinary Dividend ABLI 0.00 SEK
2023-05-05 Annual General meeting
2023-03-08 Extra General Meeting 2022
2023-02-24 Year-end Report 2022
2022-11-22 Quarterly Report 2022-Q3
2022-08-19 Quarterly Report 2022-Q2
2022-05-31 Quarterly Report 2022-Q1
2022-05-20 Annual General meeting
2022-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2022-02-22 Year-end Report 2021
2021-11-19 Quarterly Report 2021-Q3
2021-08-19 Quarterly Report 2021-Q2
2021-05-21 Ex-date Ordinary Dividend ABLI 0.00 SEK
2021-05-20 Annual General meeting
2021-05-20 Quarterly Report 2021-Q1
2021-04-29 Extra General Meeting 2021
2021-02-19 Year-end Report 2020
2020-11-20 Quarterly Report 2020-Q3
2020-08-21 Quarterly Report 2020-Q2
2020-05-22 Ex-date Ordinary Dividend ABLI 0.00 SEK
2020-05-20 Quarterly Report 2020-Q1
2020-05-20 Annual General meeting
2020-03-17 Extra General Meeting 2020
2020-02-19 Year-end Report 2019
2019-11-20 Quarterly Report 2019-Q3
2019-08-21 Quarterly Report 2019-Q2
2019-05-21 Quarterly Report 2019-Q1
2019-04-26 Ex-date Ordinary Dividend ABLI 0.00 SEK
2019-04-25 Annual General meeting
2019-02-28 Year-end Report 2018
2019-01-17 Extra General Meeting 2018
2018-11-22 Quarterly Report 2018-Q3
2018-08-21 Quarterly Report 2018-Q2
2018-05-22 Quarterly Report 2018-Q1
2018-04-30 Ex-date Ordinary Dividend ABLI 0.00 SEK
2018-04-27 Annual General meeting
2018-02-20 Year-end Report 2017
2017-11-21 Quarterly Report 2017-Q3
2017-08-17 Quarterly Report 2017-Q2
2017-05-18 Quarterly Report 2017-Q1
2017-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2017-04-27 Annual General meeting
2017-02-21 Year-end Report 2016
2016-11-22 Quarterly Report 2016-Q3
2016-08-18 Quarterly Report 2016-Q2
2016-05-31 Quarterly Report 2016-Q1
2016-04-29 Ex-date Ordinary Dividend ABLI 0.00 SEK
2016-04-28 Annual General meeting
2016-03-31 Extra General Meeting 2016
2016-02-19 Year-end Report 2015
2015-11-18 Quarterly Report 2015-Q3
2015-08-19 Quarterly Report 2015-Q2
2015-05-20 Quarterly Report 2015-Q1
2015-03-31 Ex-date Ordinary Dividend ABLI 0.00 SEK
2015-03-30 Annual General meeting
2015-02-18 Year-end Report 2014
2014-11-19 Quarterly Report 2014-Q3
2014-08-20 Quarterly Report 2014-Q2
2014-05-12 Ex-date Ordinary Dividend ABLI 0.00 SEK
2014-05-09 Quarterly Report 2014-Q1
2014-05-09 Annual General meeting
2014-02-19 Year-end Report 2013
2014-01-21 Analyst Meeting 2014
2013-12-13 Extra General Meeting 2013
2013-11-20 Quarterly Report 2013-Q3
2013-08-23 Quarterly Report 2013-Q2
2013-05-24 Quarterly Report 2013-Q1
2013-03-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2013-03-08 Annual General meeting
2013-02-05 Year-end Report 2012
2012-10-15 Quarterly Report 2012-Q3
2012-08-21 Quarterly Report 2012-Q2
2012-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2012-06-08 Annual General meeting
2012-05-31 Quarterly Report 2012-Q1
2012-04-02 Extra General Meeting 2012
2012-02-21 Year-end Report 2011
2011-11-22 Quarterly Report 2011-Q3
2011-08-23 Quarterly Report 2011-Q2
2011-06-10 Annual General meeting
2011-05-17 Quarterly Report 2011-Q1
2011-02-22 Year-end Report 2010
2010-11-18 Quarterly Report 2010-Q3
2010-08-19 Quarterly Report 2010-Q2
2010-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2010-05-20 Quarterly Report 2010-Q1
2009-11-19 Quarterly Report 2009-Q3

Description

CountrySweden
ListSmall Cap Stockholm
SectorHealth care
IndustryBiotechnology
Abliva är ett läkemedelsbolag. Bolaget utvecklar läkemedel för behandling av primära mitokondriella sjukdomar. Dessa medfödda, sällsynta och ofta mycket svåra sjukdomar uppstår då cellens energiförsörjare, mitokondrierna, inte fungerar som de ska. Portföljen omfattar projekt i olika skeden och sträcker sig från tidig upptäcktsfas till klinisk fas. Bolaget gick tidigare under namnet NeuroVive Pharmaceutical.
2023-12-14 11:45:00

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has granted orphan designation for the company’s drug candidate NV354 for the treatment of Leigh syndrome, facilitating its clinical development in neurological mitochondrial disease.

“The orphan designation by both the European Commission and the US FDA is a great recognition of the NV354 program and the first-in-class prodrug technology for the treatment of pediatric Leigh syndrome. This will facilitate the future progression to clinical development of a much-needed treatment for these patients”, said Ellen Donnelly, CEO at Abliva.

Abliva’s drug candidate NV354 is being developed for mitochondrial disease with neurologic complications, including Leigh syndrome, MELAS, and LHON. The program’s preclinical development has been completed, and in April 2023, the company was granted orphan drug designation (ODD) for NV354 in the US for the treatment of mitochondrial disease.

Abliva has now received orphan designation for NV354 also from the European Commission for the treatment of Leigh syndrome. Orphan designation in Europe offers Abliva scientific advice on study protocols, various fee reductions, and access to EU grants. If approved for EU and US orphan (drug) status when authorized for marketing, NV354 would benefit from ten years of market exclusivity within the EU and seven years within the US.